SELOPRESS

Quetiapine is an atypical antipsychotic belonging to a chemical class, the dibenzothiazepine derivatives.

The chemical designation is 2-[2-(4-dibenzo [ b,f ]thiazepin-11-yl-1-piperazinyl) ethoxy]-ethanol fumarate (2:1) (salt).

It is present in tablets as the fumarate salt.

All doses and tablet strengths are expressed as milligrams of base, not as fumarate salt.

Its molecular formula is

C 42 H 50 N 6 O 4 S 2 •C 4 H 4 O and it has a molecular weight of 883.11 (fumarate salt).

The structural formula is

Quetiapine fumarate USP is a white to off-white crystalline powder which is moderately soluble in water.

Quetiapine tablets, USP is supplied for oral administration as 25 mg (round peach), 50 mg (round, white), 100 mg (round yellow), 150 mg (round, off white to light yellow), 200 mg (round, white), 300 mg (capsule-shaped, white), and 400 mg (capsule-shaped, yellow) tablets.

Inactive ingredients are povidone, dibasic dicalcium phosphate dihydrate, microcrystalline cellulose, sodium starch glycolate, lactose monohydrate, magnesium stearate, hypromellose, polyethylene glycol and titanium dioxide.

The 25 mg tablets contain red iron oxide and yellow iron oxide and the 100 mg, 150 mg and 400 mg tablets contain only yellow iron oxide.

Each 25 mg tablet contains 28.78 mg of quetiapine fumarate USP equivalent to 25 mg quetiapine.

Each 50 mg tablet contains 57.56 mg of quetiapine fumarate USP equivalent to 50 mg quetiapine.

Each 100 mg tablet contains 115.13 mg of quetiapine fumarate USP equivalent to 100 mg quetiapine.

Each 150 mg tablet contains 172.70 mg of quetiapine fumarate USP equivalent to 150 mg quetiapine.

Each 200 mg tablet contains 230.27 mg of quetiapine fumarate USP equivalent to 200 mg quetiapine.

Each 300 mg tablet contains 345.40 mg of quetiapine fumarate USP equivalent to 300 mg quetiapine.

Each 400 mg tablet contains 460.54 mg of quetiapine fumarate USP equivalent to 400 mg quetiapine.

& USAGE Quetiapine is an atypical antipsychotic indicated for the treatment of: Schizophrenia Bipolar I disorder manic episodes Bipolar disorder, depressive episodes 1.1 Schizophrenia Quetiapine is indicated for the treatment of schizophrenia.

The efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years).

The effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. 1.2 Bipolar Disorder Quetiapine is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex.

Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) .

Quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder.

Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder.

Quetiapine is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex.

Efficacy was established in two maintenance trials in adults.

The effectiveness of quetiapine as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging.

For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms.

It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment.

Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.

Lactation History of alcoholism History of seizures History of urinary retention Sleep apnea, previous (d) Alcohol consumption Dementia Diabetes Closed angle glaucoma Closed angle glaucoma, history (of) Pregnancy Intraocular hypertension Intraocular hypertension, history Hypertriglyceridaemia Benign prostate hypertrophy Benign prostate hypertrophy, history Hypokalaemia Hypomagnesaemia Congestive heart failure Hepatic impairment Bile lithiasis Cardiovascular disease Parkinson's disease Neutropenia Neutropenia induced by a drug, history (de) Newborn exposed in utero to the medicine Intestinal obstruction Cerebrovascular pathology Suicidal-prone patient Predisposition to inhalation pneumonitis Urinary retention Elderly Subject at risk of thromboembolic accident Subject at risk of QT space prolongation Subject at risk of hypotension Subject at risk of intestinal occlusion Subject at risk of acute pancreatitis Subject under 18 Overweight Trend in drug abuse.

The mechanism of action of quetiapine in the listed indications is unclear.

However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism.

The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2, but greater activity at 5HT2A receptors, than the parent drug (quetiapine). 12.2 Pharmacodynamics Quetiapine and its metabolite, norquetiapine, have affinity for multiple neurotransmitter receptors with norquetiapine binding with higher affinity than quetiapine in general.

The Ki values for quetiapine and norquetiapine at the dopamine D1 are 428/99.8 nM, at D2 626/489nM, at serotonin 5HT1A 1040/191 nM at 5HT2A 38/2.9 nM, at histamine H1 4.4/1.1 nM, at muscarinic M1 1086/38.3 nM, and at adrenergic α1b 14.6/46.4 nM and, at α2 receptors 617/1290 nM, respectively.

Quetiapine and norquetiapine lack appreciable affinity to the benzodiazepine receptors.

In clinical trials, quetiapine was not associated with a persistent increase in QT intervals.

However, the QT effect was not systematically evaluated in a thorough QT study.

In post marketing experience, there were cases reported of QT prolongation in patients who overdosed on quetiapine, in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase QT interval. 12.3 Pharmacokinetics Adults Quetiapine activity is primarily due to the parent drug.

The multiple-dose pharmacokinetics of quetiapine are dose-proportional within the proposed clinical dose range, and quetiapine accumulation is predictable upon multiple dosing.

Elimination of quetiapine is mainly via hepatic metabolism with a mean terminal half-life of about 6 hours within the proposed clinical dose range.

Steady-state concentrations are expected to be achieved within two days of dosing.

Quetiapine is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.

At steady-state the pharmacokinetics of the parent compound, in children and adolescents (10-17 years of age), were similar to adults.

However, when adjusted for dose and weight, AUC and Cmax of the parent compound were 41% and 39% lower, respectively, in children and adolescents than in adults.

For the active metabolite, norquetiapine, AUC and C max were 45% and 31% higher, respectively, in children and adolescents than in adults.

When adjusted for dose and weight, the pharmacokinetics of the metabolite, norquetiapine, was similar between children and adolescents and adults.

Quetiapine is rapidly absorbed after oral administration, reaching peak plasma concentrations in 1.5 hours.

The tablet formulation is 100% bioavailable relative to solution.

The bioavailability of quetiapine is marginally affected by administration with food, with C max and AUC values increased by 25% and 15%, respectively.

Quetiapine is widely distributed throughout the body with an apparent volume of distribution of 10±4 L/kg. It is 83% bound to plasma proteins at therapeutic concentrations.

In vitro, quetiapine did not affect the binding of warfarin or diazepam to human serum albumin.

In turn, neither warfarin nor diazepam altered the binding of quetiapine.

Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized.

Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.

Quetiapine is extensively metabolized by the liver.

The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive.

In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine.

Oral clearance of quetiapine was reduced by 40% in elderly patients (≥ 65 years, n=9) compared to young patients (n=12), and dosing adjustment may be necessary.

There is no gender effect on the pharmacokinetics of quetiapine.

There is no race effect on the pharmacokinetics of quetiapine.

Smoking has no effect on the oral clearance of quetiapine.

Patients with severe renal impairment (Clcr=10-30 mL/min/1.73 m2, n=8) had a 25% lower mean oral clearance than normal subjects (Clcr > 80 mL/min/1.73 m2, n=8), but plasma quetiapine concentrations in the subjects with renal insufficiency were within the range of concentrations seen in normal subjects receiving the same dose.

Dosage adjustment is therefore not needed in these patients.

Hepatically impaired patients (n=8) had a 30% lower mean oral clearance of quetiapine than normal subjects.

In two of the 8 hepatically impaired patients, AUC and C max were 3 times higher than those observed typically in healthy subjects.

Since quetiapine is extensively metabolized by the liver, higher plasma levels are expected in the hepatically impaired population, and dosage adjustment may be needed [s ee Dosage and Administration and Use in Specific Populations.

The in vivo assessments of effect of other drugs on the pharmacokinetics of quetiapine are summarized in Table 17.

Table 17: The Effect of Other Drugs on the Pharmacokinetics of Quetiapine Coadministered Drug Dose Schedules Effect on Quetiapine Pharmacokinetics Coadministered Drug Quetiapine Phenytoin 100 mg three times daily 250 mg three times daily 5-fold increase in oral clearance Divalproex 500 mg twice daily 150 mg twice daily 17% increase mean max plasma concentration at steady state.

No effect on absorption or mean oral clearance Thioridazine 200 mg twice daily 300 mg twice daily 65% increase in oral clearance Cimetidine 400 mg three times daily for 4 days 150 mg three times daily 20% decrease in mean oral clearance Ketoconazole (potent CYP 3A4 inhibitor) 200 mg once daily for 4 days 25 mg single dose 84% decrease in oral clearance resulting in a 6.2-fold increase in AUC of quetiapine Fluoxetine 60 mg once daily 300 mg twice daily No change in steady state PK Imipramine 75 mg twice daily 300 mg twice daily No change in steady state PK Haloperidol 7.5 mg twice daily 300 mg twice daily No change in steady state PK Risperidone 3 mg twice daily 300 mg twice daily No change in steady state PK In vitro enzyme inhibition data suggest that quetiapine and of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes CYP 1A2, 2C9, 2C19, 2D6, and 3A4.

Quetiapine at doses of 750 mg/day did not affect the single dose pharmacokinetics of antipyrine, lithium, or lorazepam (Table 18) .

Table 18: The Effect of Quetiapine on the Pharmacokinetics of Other Drugs Coadministered drug Dose schedules Effect on other drugs pharmacokinetics Coadministered drug Quetiapine Lorazepam 2 mg, single dose 250 mg three times daily Oral clearance of lorazepam reduced by 20% Divalproex 500 mg twice daily 150 mg twice daily Cmax and AUC of free valproic acid at steady.

• state was decreased by 10-12% Lithium Up to 2400 mg/day given in twice daily doses 250 mg three times daily No effect on steady-state pharmacokinetics of lithium Antipyrine 1 g, single dose 250 mg three times daily No effect on clearance of antipyrine or urinary recovery of its metabolites.

Quétiapine: Atypical mechanism of action Antipsychotic, quetiapine and its active plasma metabolite in humans, norquétiapine, bind to a wide range of neurotransmitter receptors.

Quetiapine and norquétiapine have an affinity for serotonin cerebral (5-HT2) and dopamine D1 and D2 receptors.

This double antagonism of receptors is considered to be associated with a higher selectivity for 5-HT2 receptors compared to D2 receptors, which contributes to clinical antipsychotic properties and to the low tendency of quetiapine to produce extrapyramidal symptoms (EPS) compared to typical antipsychotics.

Norquétiapine has a high affinity for noradrenaline carrier (NAT).

Quetiapine and norquétiapine also exhibit significant affinity for histaminergic and alpha1-adrenergic receptors.

Norquétiapine has a high affinity for noradrenaline receptors and a low affinity for the receptors.

• Free tri-iodothyronin decreased (Uncommon)
• Free thyroxine decreased (Common)
• Hyperprolactinaemia (Common)
• T3 (decrease) (Common)
• Hyponatremia (Uncommon)
• TSH (increase) (Common)
• Hyperglycaemia (Common)
• Eosinophilia (Common)
• HDL (decrease) (Very common)
• Neutropenia (Uncommon)
• Hypercholesterolaemia (Very common)
• ALT (increase) (Common)
• T4 (decrease) (Common)
• ASAT (increase) (Uncommon)
• Hypertriglyceridaemia (Very common)
• Gamma GT (increase) (Common)
• Blood globinaemia (decrease) (Very common)
• Neutralophiles decreased (Common)
• KPC (increase) (Rare)
• LDL (increase)
• Stevens-Johnson Syndrome (Very rare)
• Toxic epidermal necrolysis Generalised acute exanthemous pusulosis
• Polymorphic Erythema Sexual disorder (Uncommon)
• Peripheral edema (Common)
• Fever (Common)
• Asthenia (Common)
• Metabolic syndrome (Rare)
• Hypothermia (Rare)
• Fall Hypothyroidism (Uncommon)
• Inappropriate antidiuretic hormone secretion syndrome (IADH) (Very rare)
• Galactorrhoea (Rare)
• Menstrual disorder (Rare)
• Breast volume (increase) (Rare)
• Anemia (Uncommon)
• Leucopenia (Common)
• Thrombocytopenia (Uncommon)
• Agranulocytosis (Rare)
• Ictery (Rare)
• Hepatitis (Rare)
• Hypersensitivity (Uncommon)
• Anaphylactic reaction (Very rare)
• Angioedema (Very rare)
• DRESS syndrome Appetite increased (Very common)
• Diabetes (disequilibrium) (Uncommon)
• Diabetes (Uncommon)
• Weight (increase) (Very common)
• Dysphagia (Uncommon)
• Blurty vision (Common)
• Oral dryness (Very common)
• Vertigo (Very common)
• Rhinite (Common)
• Suicidal behaviour (Common)
• Irritability (Common)
• Suicidal ideation (Common)
• Nightmare (Common)
• Mental confusion (Uncommon)
• Abnormal dreams (Common)
• Sleep-related eating disorders (Rare)
• Blood pressure (increase) (Very common)
• Bradycardia (Uncommon)
• Tachycardia (Common)
• Syncope (Common)
• Palpitation (Common)
• QT space extension (Uncommon)
• Orthostatic hypotension (Common)
• Venous thromboembolic accident (Rare)
• Sudden death Ventricular arrhythmia Myocarditis Skin vasculitis Hypotension Torsades de pointes
• Cardiovascular disease Cardiac arrest Dyspepsia (Common)
• Constipation (Common)
• Vomiting (Common)
• Pancreatitis (Rare)
• Intestinal occlusion (Rare)
• Ileus (Rare)
• Rhabdomyolysis (Very rare)
• Convulsions (Uncommon)
• Headache (Very common)
• Late dyskinesia (Uncommon)
• Dysarthria (Common)
• Restless leg syndrome (Uncommon)
• Somnolence (Very common)
• Extrapyramidal syndrome (Very common)
• Somnambulism (Rare)
• Stroke Dyspnoea (Common)
• Weaning syndrome (Very common)
• Neuroleptic malignant syndrome (Rare)
• Neonatal withdrawal syndrome Urinary retention (Uncommon)
• Priapism (Rare).

In clinical trials, survival has been reported in acute overdoses of up to 30 grams of quetiapine.

Most patients who overdosed experienced no adverse reactions or recovered fully from the reported reactions.

Death has been reported in a clinical trial following an overdose of 13.6 grams of quetiapine alone.

In general, reported signs and symptoms were those resulting from an exaggeration of the drug’s known pharmacological effects, i.e., drowsiness, sedation, tachycardia, hypotension, and anticholinergic toxicity including coma and delirium.

Patients with pre-existing severe cardiovascular disease may be at an increased risk of the effects of overdose.

One case, involving an estimated overdose of 9,600 mg, was associated with hypokalemia and first.

• degree heart block.

In post-marketing experience, there were cases reported of QT prolongation with overdose. 10.2 Management of Overdosage Establish and maintain an airway and ensure adequate oxygenation and ventilation.

Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.

Appropriate supportive measures are the mainstay of management.

For the most up-to-date information on the management of quetiapine overdosage, contact a certified Regional Poison Control Center.

Hypersensitivity to quetiapine or to any excipients in the quetiapine formulation.

Anaphylactic reactions have been reported in patients treated with quetiapine.

Known hypersensitivity to quetiapine or any components in the formulation.

& ADMINISTRATION · Quetiapine tablets, USP can be taken with or without food Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults 25 mg twice daily to 750 mg/day 750 mg/day Schizophrenia-Adolescents (13 to 17 years) 25 mg twice daily to 800 mg/day 800 mg/day Bipolar Mania.

• Adults Monotherapy or as an adjunct to lithium or divalproex 50 mg twice daily to 800 mg/day 800 mg/day Bipolar Mania.

• Children and Adolescents (10 to 17 years), Monotherapy 25 mg twice daily to 600 mg/day 600 mg/day Bipolar Depression-Adults 50 mg once daily at bedtime 300 mg/day 300 mg/day Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration and careful monitoring during the initial dosing period in the elderly Hepatic Impairment: Lower starting dose (25 mg/day) and slower titration may be needed 2.1 Important Administration Instructions Quetiapine tablets, USP can be taken with or without food. 2.2 Recommended Dosing The recommended initial dose, titration, dose range and maximum quetiapine dose for each approved indication is displayed in Table 1.

After initial dosing, adjustments can be made upwards or downwards, if necessary, depending upon the clinical response and tolerability of the patient.

Table 1: Recommended Dosing for quetiapine Indication Initial Dose and Titration Recommended Dose Maximum Dose Schizophrenia-Adults Day 1: 25 mg twice daily.

Increase in increments of 25 mg-50 mg divided two or three times on Days and 3 to range of to 400 mg by Day 4.

Further adjustments can be made in increments of to 50 mg twice a day, in intervals of not less than 2 days. 150 to 750 mg/day 750 mg/day Schizophrenia.

• Adolescents (13 to 17 years) Day 1: 25 mg twice daily.

Day 2: Twice daily dosing totaling 100 mg. Day 3: Twice daily dosing totaling 200 mg. Day 4: Twice daily dosing totaling 300 mg. Day 5: Twice daily dosing totaling 400 mg. Further adjustments should be in increments no greater than 100 mg/day within the recommended dose range of 400-800 mg/day. Based on response and tolerability, may be administered three times daily. 400 to 800 mg/day 800 mg/day Schizophrenia-Maintenance Not applicable. 400 to 800 mg/day 800 mg/day Bipolar Mania.

• Adults Monotherapy or as an adjunct to lithium or divalproex Day 1: Twice daily dosing totaling 100 mg. Day 2: Twice daily dosing totaling 200 mg. Day 3: Twice daily dosing totaling 300 mg. Day 4: Twice daily dosing totaling 400 mg. Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no greater than 200 mg/day. 400 to 800 mg/day 800 mg/day Bipolar Mania.

• Children and Adolescents (10 to 17 years), Monotherapy Day 1: 25 mg twice daily.

Day 2: Twice daily dosing totaling 100 mg. Day 3: Twice daily dosing totaling 200 mg. Day 4: Twice daily dosing totaling 300 mg. Day 5: Twice daily dosing totaling 400 mg. Further adjustments should be in increments no greater than 100 mg/day within the recommended dose range of 400-600 mg/day. Based on response and tolerability, may be administered three times daily. 400 to 600 mg/day 600 mg/day Bipolar Depression.

• Adults Administer once daily at bedtime.

Day 1: 50 mg Day 2: 100 mg Day 3: 200 mg Day 4: 300 mg 300 mg/day 300 mg/day Bipolar I Disorder Maintenance Therapy.

• Adults Administer twice daily totaling 400-800 mg/day as adjunct to lithium or divalproex.

Generally, in the maintenance phase, patients continued on the same dose on which they were stabilized. 400 to 800 mg/day 800 mg/day Maintenance Treatment for Schizophrenia and Bipolar I Disorder Maintenance Treatment– Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment. 2.3 Dose Modifications in Elderly Patients Consideration should be given to a slower rate of dose titration and a lower target dose in the elderly and in patients who are debilitated or who have a predisposition to hypotensive reactions.

When indicated, dose escalation should be performed with caution in these patients.

Elderly patients should be started on quetiapine 50 mg/day and the dose can be increased in increments of 50 mg/day depending on the clinical response and tolerability of the individual patient. 2.4 Dose Modifications in Hepatically Impaired Patients Patients with hepatic impairment should be started on 25 mg/day. The dose should be increased daily in increments of 25 mg/day.

• 50 mg/day to an effective dose, depending on the clinical response and tolerability of the patient. 2.5 Dose Modifications when used with CYP3A4 Inhibitors Quetiapine dose should be reduced to one sixth of original dose when co-medicated with a potent CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc).

When the

CYP3A4 inhibitor is discontinued, the dose of quetiapine should be increased by 6-fold. 2.6 Dose Modifications when used with CYP3A4 Inducers Quetiapine dose should be increased up to 5-fold of the original dose when used in combination with a chronic treatment (e.g., greater than to 14 days) of a potent CYP3A4 inducer (e.g., phenytoin, carbamazepine, rifampin, avasimibe, St. John’s wort etc).

The dose should be titrated based on the clinical response and tolerability of the individual patient.

CYP3A4 inducer is discontinued, the dose of quetiapine should be reduced to the original level within 7-14 days. 2.7 Re-initiation of Treatment in Patients Previously Discontinued Although there are no data to specifically address re-initiation of treatment, it is recommended that when restarting therapy of patients who have been off quetiapine for more than one.

• week, the initial dosing schedule should be followed.

When restarting patients who have been off quetiapine for less than one-week, gradual dose escalation may not be required and the maintenance dose may be re-initiated. 2.8 Switching from Antipsychotics There are no systematically collected data to specifically address switching patients with schizophrenia from antipsychotics to quetiapine, or concerning concomitant administration with antipsychotics.

While immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others.

In all cases, the period of overlapping antipsychotic administration should be minimized.

When switching patients with schizophrenia from depot antipsychotics, if medically appropriate, initiate quetiapine therapy in place of the next scheduled injection.

The need for continuing existing

EPS medication should be re-evaluated periodically.

Quetiapine tablets, USP 100 mg Yellow coloured, film coated, round shape, biconvex tablets, debossed with "261" on one side and plain on other side.

NDC 71335-1462-1: 100 Tablets in a BOTTLE NDC 71335-1462-2: 30 Tablets in a BOTTLE NDC 71335-1462-3: 120 Tablets in a BOTTLE NDC 71335-1462-4: 60 Tablets in a BOTTLE NDC 71335-1462-5: 90 Tablets in a BOTTLE NDC 71335-1462-6: 15 Tablets in a BOTTLE Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .

Repackaged/Relabeled by: Bryant Ranch Prepack, Inc.

Burbank, CA 91504.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including quetiapine tablets, during pregnancy.

Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at.

Neonates exposed to antipsychotic drugs ( including quetiapine tablet) during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery.

Overall available data from published epidemiologic studies of pregnant women exposed to quetiapine have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

There are risks to the mother associated with untreated schizophrenia, bipolar I, or major depressive disorder, and with exposure to antipsychotics, including, quetiapine tablet during pregnancy.

In animal studies, embryo-fetal toxicity occurred including delays in skeletal ossification at approximately and 2 times the maximum recommended human dose (MRHD) of 800 mg/day in both rats and rabbits, and an increased incidence of carpal/tarsal flexure (minor soft tissue anomaly) in rabbit fetuses at approximately 2 times the MRHD.

In addition, fetal weights were decreased in both species.

Maternal toxicity (observed as decreased body weights and/or death) occurred at 2 times the MRHD in rats and approximately 1-2 times the MRHD in rabbits.

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the

U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and to 20%, respectively.

Disease-associated maternal and/or fetal risk There is a risk to the mother from untreated schizophrenia, or bipolar I disorder, including increased risk of relapse, hospitalization, and suicide.

Schizophrenia and bipolar

I disorder are associated with increased adverse perinatal outcomes, including preterm birth.

It is not known if this is a direct result of the illness or other comorbid factors.

A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy.

The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressants.

Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

Fetal/neonatal adverse reactions Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs, including quetiapine tablets, during the third trimester of pregnancy.

These symptoms varied in severity.

Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.

Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization.

Published data from observational studies, birth registries, and case reports on the use of atypical antipsychotics during pregnancy do not report a clear association with antipsychotics and major birth defects.

A retrospective cohort study from a

Medicaid database of 9258 women exposed to antipsychotics during pregnancy did not indicate an overall increased risk of major birth defects.

When pregnant rats and rabbits were exposed to quetiapine during organogenesis, there was no teratogenic effect in fetuses.

Doses were and 200 mg/kg in rats and and 100 mg/kg in rabbits which are approximately 0.3, 0.6 and 2-times (rats) and 0.6, 1 and 2-times (rabbits) the MRHD, for schizophrenia of 800 mg/day based on mg/m 2 body surface area.

However, there was evidence of embryo-fetal toxicity, including delays in skeletal ossification at approximately and 2 times the MRHD of 800 mg/day in both rats and rabbits and an increased incidence of carpal/tarsal flexure (minor soft tissue anomaly) in rabbit fetuses at approximately 2 times the MRHD.

Maternal toxicity (observed as decreased body weights and/or death) occurred at 2 times the MRHD in rats and at approximately 1-2 times the MRHD (all doses tested) in rabbits.

In a peri/postnatal reproductive study in rats, no drug-related effects were observed when pregnant dams were treated with quetiapine at doses 0.01, 0.1, and 0.2 times the MRHD of 800 mg/day based on mg/m 2 body surface area.

However, in a preliminary peri/postnatal study, there were increases in fetal and pup death, and decreases in mean litter weight at 3 times the MRHD.

Females and Males of Reproductive Potential Infertility Females Based on the pharmacologic action of quetiapine (D2 antagonism), treatment with quetiapine tablets may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential.

In general, the adverse reactions observed in children and adolescents during the clinical trials were similar to those in the adult population with few exceptions.

Increases in systolic and diastolic blood pressure occurred in children and adolescents and did not occur in adults.

Orthostatic hypotension occurred more frequently in adults (4-7%) compared to children and adolescents (< 1%) .

The efficacy and safety of quetiapine in the treatment of schizophrenia in adolescents aged to 17 years were demonstrated in one 6-week, double-blind, placebo-controlled trial.

Safety and effectiveness of quetiapine in pediatric patients less than 13 years of age with schizophrenia have not been established.

The safety and effectiveness of quetiapine in the maintenance treatment of bipolar disorder has not been established in pediatric patients less than 18 years of age.

The safety and effectiveness of quetiapine in the maintenance treatment of schizophrenia has not been established in any patient population, including pediatric patients.

The efficacy and safety of quetiapine in the treatment of mania in children and adolescents ages to 17 years with bipolar I disorder was demonstrated in a 3-week, double-blind, placebo-controlled, multicenter trial.

Safety and effectiveness of quetiapine in pediatric patients less than 10 years of age with bipolar mania have not been established.

Bipolar Depression Safety and effectiveness of

Quetiapine in pediatric patients less than 18 years of age with bipolar depression have not been established.

A clinical trial with SEROQUEL

XR was conducted in children and adolescents (10 to 17 years of age) with bipolar depression, efficacy was not established.

Some differences in the pharmacokinetics of quetiapine were noted between children/adolescents (10 to 17 years of age) and adults.

When adjusted for weight, the AUC and Cmax of quetiapine were 41% and 39% lower, respectively, in children and adolescents compared to adults.

The pharmacokinetics of the active metabolite, norquetiapine, were similar between children/adolescents and adults after adjusting for weight.

Of the approximately 3700 patients in clinical studies with quetiapine, 7% were 65 years of age or over.

In general, there was no indication of any different tolerability of quetiapine in the elderly compared to younger adults.

Nevertheless, the presence of factors that might decrease pharmacokinetic clearance, increase the pharmacodynamic response to quetiapine, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period in the elderly.

The mean plasma clearance of quetiapine was reduced by 30% to 50% in elderly patients when compared to younger patients.